Quality of life after breast-conserving surgery for women with non-low-risk ductal carcinoma in situ
Breast irradiation proportionately halves the risk of ipsilateral breast recurrence, with an absolute reduction of 15·2% (p
Gespeichert in:
| Veröffentlicht in: | The lancet oncology 2020-05, Vol.21 (5), p.612-614 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 614 |
|---|---|
| container_issue | 5 |
| container_start_page | 612 |
| container_title | The lancet oncology |
| container_volume | 21 |
| creator | Benson, John R |
| description | Breast irradiation proportionately halves the risk of ipsilateral breast recurrence, with an absolute reduction of 15·2% (p |
| doi_str_mv | 10.1016/S1470-2045(20)30135-2 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2382657809</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1470204520301352</els_id><sourcerecordid>2425647426</sourcerecordid><originalsourceid>FETCH-LOGICAL-c393t-a3e7c106e0856166a2f088996f986f0159130608d9ddbaea202f4fcab02e18453</originalsourceid><addsrcrecordid>eNqFkU1v1DAQhi0EomXhJ4AscSmHwNiOHeeEqoovqRJCwNnyOuPiktjFdrraf4-7Wzhw4TIzGj3zofcl5DmD1wyYevOV9QN0HHp5xuGVACZkxx-Q09buO9lr_fBQH5ET8qSUawA2MJCPyYngHIQah1MyfVntHOqeJk_n4JFaXzHTbUZbaudSLJhvQ7yiZc1XmPfUp0x3acFId6H-oDHFbk67Lofyk06rq3amzmYXYlosDZGWUNen5JG3c8Fn93lDvr9_9-3iY3f5-cOni_PLzolR1M4KHBwDhaClYkpZ7kHrcVR-1MoDkyMToEBP4zRtLVoO3Pfe2S1wZLqXYkPOjntvcvq1YqlmCcXhPNuIaS2GC82VHDSMDX35D3qd1hzbd4b3XKqmIleNkkfK5VRKRm9uclhs3hsG5s4Gc7DB3GncgjnY0M5syIv77et2wenv1B_dG_D2CGCT4zZgNsUFjA6nkNFVM6XwnxO_AYyllns</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2425647426</pqid></control><display><type>article</type><title>Quality of life after breast-conserving surgery for women with non-low-risk ductal carcinoma in situ</title><source>Access via ScienceDirect (Elsevier)</source><source>ProQuest Central UK/Ireland</source><creator>Benson, John R</creator><creatorcontrib>Benson, John R</creatorcontrib><description>Breast irradiation proportionately halves the risk of ipsilateral breast recurrence, with an absolute reduction of 15·2% (p<0·00001) at 10 years reported in a meta-analysis.3 A low event rate might preclude any reduction in mortality from breast cancer or all-cause mortality.3,4 Any benefits of adjuvant therapies on local control must be balanced against potentially harmful side-effects plus patient inconvenience and cost. Contemporary guidelines recommend radiotherapy for most patients with non-low-risk ductal carcinoma in situ, but boost criteria remain uncertain.5–7 Historically, trials of conservation therapy for ductal carcinoma in situ used a conventional radiotherapy schedule (50 Gy, 25 fractions, over 5 weeks) with a discretionary tumour bed boost for 5% and 9% of patients in two trials (based on factors such as young age and margin status).4 Madeleine King and colleagues8 report secondary outcome data from the first prospective study examining the effect of different radiation treatment schedules on PROs following breast-conserving surgery for non-low-risk ductal carcinoma in situ. Cosmetic status deteriorated significantly from baseline to the end of treatment, and this difference was more pronounced for the tumour bed boost group than for the no boost group (0·13 [95% CI 0·06–0·20], p=0·00021). [...]despite improvements following radiotherapy, these differences were evident at all timepoints (global p=0·0001; Hochberg-adjusted p=0·002) and persisted through to 24 months (0·13 [95% CI 0·06–0·20]; p=0·00021).</description><identifier>ISSN: 1470-2045</identifier><identifier>EISSN: 1474-5488</identifier><identifier>DOI: 10.1016/S1470-2045(20)30135-2</identifier><identifier>PMID: 32203697</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Breast cancer ; Cancer therapies ; Clinical trials ; Endocrine therapy ; Mastectomy ; Mortality ; Patients ; Quality of life ; Radiation therapy ; Self image ; Surgery ; Tumors</subject><ispartof>The lancet oncology, 2020-05, Vol.21 (5), p.612-614</ispartof><rights>2020 Elsevier Ltd</rights><rights>2020. Elsevier Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c393t-a3e7c106e0856166a2f088996f986f0159130608d9ddbaea202f4fcab02e18453</citedby><cites>FETCH-LOGICAL-c393t-a3e7c106e0856166a2f088996f986f0159130608d9ddbaea202f4fcab02e18453</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/2425647426?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995,64385,64387,64389,72469</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32203697$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Benson, John R</creatorcontrib><title>Quality of life after breast-conserving surgery for women with non-low-risk ductal carcinoma in situ</title><title>The lancet oncology</title><addtitle>Lancet Oncol</addtitle><description>Breast irradiation proportionately halves the risk of ipsilateral breast recurrence, with an absolute reduction of 15·2% (p<0·00001) at 10 years reported in a meta-analysis.3 A low event rate might preclude any reduction in mortality from breast cancer or all-cause mortality.3,4 Any benefits of adjuvant therapies on local control must be balanced against potentially harmful side-effects plus patient inconvenience and cost. Contemporary guidelines recommend radiotherapy for most patients with non-low-risk ductal carcinoma in situ, but boost criteria remain uncertain.5–7 Historically, trials of conservation therapy for ductal carcinoma in situ used a conventional radiotherapy schedule (50 Gy, 25 fractions, over 5 weeks) with a discretionary tumour bed boost for 5% and 9% of patients in two trials (based on factors such as young age and margin status).4 Madeleine King and colleagues8 report secondary outcome data from the first prospective study examining the effect of different radiation treatment schedules on PROs following breast-conserving surgery for non-low-risk ductal carcinoma in situ. Cosmetic status deteriorated significantly from baseline to the end of treatment, and this difference was more pronounced for the tumour bed boost group than for the no boost group (0·13 [95% CI 0·06–0·20], p=0·00021). [...]despite improvements following radiotherapy, these differences were evident at all timepoints (global p=0·0001; Hochberg-adjusted p=0·002) and persisted through to 24 months (0·13 [95% CI 0·06–0·20]; p=0·00021).</description><subject>Breast cancer</subject><subject>Cancer therapies</subject><subject>Clinical trials</subject><subject>Endocrine therapy</subject><subject>Mastectomy</subject><subject>Mortality</subject><subject>Patients</subject><subject>Quality of life</subject><subject>Radiation therapy</subject><subject>Self image</subject><subject>Surgery</subject><subject>Tumors</subject><issn>1470-2045</issn><issn>1474-5488</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNqFkU1v1DAQhi0EomXhJ4AscSmHwNiOHeeEqoovqRJCwNnyOuPiktjFdrraf4-7Wzhw4TIzGj3zofcl5DmD1wyYevOV9QN0HHp5xuGVACZkxx-Q09buO9lr_fBQH5ET8qSUawA2MJCPyYngHIQah1MyfVntHOqeJk_n4JFaXzHTbUZbaudSLJhvQ7yiZc1XmPfUp0x3acFId6H-oDHFbk67Lofyk06rq3amzmYXYlosDZGWUNen5JG3c8Fn93lDvr9_9-3iY3f5-cOni_PLzolR1M4KHBwDhaClYkpZ7kHrcVR-1MoDkyMToEBP4zRtLVoO3Pfe2S1wZLqXYkPOjntvcvq1YqlmCcXhPNuIaS2GC82VHDSMDX35D3qd1hzbd4b3XKqmIleNkkfK5VRKRm9uclhs3hsG5s4Gc7DB3GncgjnY0M5syIv77et2wenv1B_dG_D2CGCT4zZgNsUFjA6nkNFVM6XwnxO_AYyllns</recordid><startdate>202005</startdate><enddate>202005</enddate><creator>Benson, John R</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>3V.</scope><scope>7RV</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8C2</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope></search><sort><creationdate>202005</creationdate><title>Quality of life after breast-conserving surgery for women with non-low-risk ductal carcinoma in situ</title><author>Benson, John R</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c393t-a3e7c106e0856166a2f088996f986f0159130608d9ddbaea202f4fcab02e18453</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Breast cancer</topic><topic>Cancer therapies</topic><topic>Clinical trials</topic><topic>Endocrine therapy</topic><topic>Mastectomy</topic><topic>Mortality</topic><topic>Patients</topic><topic>Quality of life</topic><topic>Radiation therapy</topic><topic>Self image</topic><topic>Surgery</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Benson, John R</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Lancet Titles</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><jtitle>The lancet oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Benson, John R</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Quality of life after breast-conserving surgery for women with non-low-risk ductal carcinoma in situ</atitle><jtitle>The lancet oncology</jtitle><addtitle>Lancet Oncol</addtitle><date>2020-05</date><risdate>2020</risdate><volume>21</volume><issue>5</issue><spage>612</spage><epage>614</epage><pages>612-614</pages><issn>1470-2045</issn><eissn>1474-5488</eissn><abstract>Breast irradiation proportionately halves the risk of ipsilateral breast recurrence, with an absolute reduction of 15·2% (p<0·00001) at 10 years reported in a meta-analysis.3 A low event rate might preclude any reduction in mortality from breast cancer or all-cause mortality.3,4 Any benefits of adjuvant therapies on local control must be balanced against potentially harmful side-effects plus patient inconvenience and cost. Contemporary guidelines recommend radiotherapy for most patients with non-low-risk ductal carcinoma in situ, but boost criteria remain uncertain.5–7 Historically, trials of conservation therapy for ductal carcinoma in situ used a conventional radiotherapy schedule (50 Gy, 25 fractions, over 5 weeks) with a discretionary tumour bed boost for 5% and 9% of patients in two trials (based on factors such as young age and margin status).4 Madeleine King and colleagues8 report secondary outcome data from the first prospective study examining the effect of different radiation treatment schedules on PROs following breast-conserving surgery for non-low-risk ductal carcinoma in situ. Cosmetic status deteriorated significantly from baseline to the end of treatment, and this difference was more pronounced for the tumour bed boost group than for the no boost group (0·13 [95% CI 0·06–0·20], p=0·00021). [...]despite improvements following radiotherapy, these differences were evident at all timepoints (global p=0·0001; Hochberg-adjusted p=0·002) and persisted through to 24 months (0·13 [95% CI 0·06–0·20]; p=0·00021).</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>32203697</pmid><doi>10.1016/S1470-2045(20)30135-2</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1470-2045 |
| ispartof | The lancet oncology, 2020-05, Vol.21 (5), p.612-614 |
| issn | 1470-2045 1474-5488 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2382657809 |
| source | Access via ScienceDirect (Elsevier); ProQuest Central UK/Ireland |
| subjects | Breast cancer Cancer therapies Clinical trials Endocrine therapy Mastectomy Mortality Patients Quality of life Radiation therapy Self image Surgery Tumors |
| title | Quality of life after breast-conserving surgery for women with non-low-risk ductal carcinoma in situ |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T21%3A52%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Quality%20of%20life%20after%20breast-conserving%20surgery%20for%20women%20with%20non-low-risk%20ductal%20carcinoma%20in%20situ&rft.jtitle=The%20lancet%20oncology&rft.au=Benson,%20John%20R&rft.date=2020-05&rft.volume=21&rft.issue=5&rft.spage=612&rft.epage=614&rft.pages=612-614&rft.issn=1470-2045&rft.eissn=1474-5488&rft_id=info:doi/10.1016/S1470-2045(20)30135-2&rft_dat=%3Cproquest_cross%3E2425647426%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2425647426&rft_id=info:pmid/32203697&rft_els_id=S1470204520301352&rfr_iscdi=true |